Document is current
Any future updates will be listed below
-
Authors
Vasilev, Kirill
Hoxie, Irene
Puente-Massaguer, Eduard
Yueh, Joshua
Bhavsar, Disha
Singh, Maya
Mallett, Corey P.
Zimmermann, Joseph
Krammer, Florian
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (75N93019C00051)
- License Information
-
More Information
Article History
Received: 28 January 2025
Accepted: 24 June 2025
First Online: 10 July 2025
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor and F.K. has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is co-founder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Curevac, Gritstone, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. C.P.M. is an employee of the GSK group of companies and owns shares in GSK. All other authors declare no competing interests.
